S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
NASDAQ:DBTX

Decibel Therapeutics Stock Forecast, Price & News

$4.32
+0.23 (+5.62%)
(As of 01/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.10
$4.36
50-Day Range
$4.09
$7.52
52-Week Range
$3.91
$24.39
Volume
72,189 shs
Average Volume
58,594 shs
Market Capitalization
$107.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive DBTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Decibel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Decibel Therapeutics logo

About Decibel Therapeutics

Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the inner ear; and DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.

Headlines

Decibel Therapeutics, Inc. Common Stock (DBTX)
January 21, 2022 |  nasdaq.com
3 ‘Strong Buy’ Small-Cap Stocks With Plenty of Upside
October 28, 2021 |  finance.yahoo.com
Decibel Therapeutics, Inc. (DBTX)
October 23, 2021 |  realmoney.thestreet.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DBTX
Phone
N/A
Fax
N/A
Employees
40
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Net Income
$-39.34 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$107.67 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/10/2021
Today
1/28/2022
Next Earnings (Estimated)
4/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.20 out of 5 stars

Medical Sector

394th out of 1,417 stocks

Pharmaceutical Preparations Industry

178th out of 683 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -












Decibel Therapeutics (NASDAQ:DBTX) Frequently Asked Questions

Is Decibel Therapeutics a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Decibel Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Decibel Therapeutics stock.
View analyst ratings for Decibel Therapeutics
or view top-rated stocks.

Are investors shorting Decibel Therapeutics?

Decibel Therapeutics saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 409,200 shares, an increase of 30.1% from the December 31st total of 314,500 shares. Based on an average daily volume of 67,400 shares, the days-to-cover ratio is presently 6.1 days.
View Decibel Therapeutics' Short Interest
.

When is Decibel Therapeutics' next earnings date?

Decibel Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, April 4th 2022.
View our earnings forecast for Decibel Therapeutics
.

How were Decibel Therapeutics' earnings last quarter?

Decibel Therapeutics, Inc. (NASDAQ:DBTX) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.43) by $0.23.
View Decibel Therapeutics' earnings history
.

What price target have analysts set for DBTX?

7 Wall Street analysts have issued 12 month price targets for Decibel Therapeutics' stock. Their forecasts range from $14.00 to $30.00. On average, they anticipate Decibel Therapeutics' share price to reach $22.43 in the next twelve months. This suggests a possible upside of 419.2% from the stock's current price.
View analysts' price targets for Decibel Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Decibel Therapeutics' key executives?

Decibel Therapeutics' management team includes the following people:
  • Dr. Laurence E. Reid, Pres, CEO & Director (Age 57, Pay $789.5k) (LinkedIn Profile)
  • Ms. Anna Trask, Chief People, Community & Culture Officer (Age 63, Pay $485.44k) (LinkedIn Profile)
  • Mr. John J. Lee, Chief Devel. Officer (Age 53, Pay $808.62k)
  • Mr. M. Charles Liberman, Co-Founder & Member of Scientific Advisory Board
  • Dr. Gabriel Corfas, Co-Founder & Member of Scientific Advisory Board
  • Dr. Ulrich Müller, Co-Founder & Member of Scientific Advisory Board
  • Dr. Albert S. B. Edge, Co-Founder & Member of Scientific Advisory Board (Age 66)
  • Dr. Elisabeth Leiderman M.B.A., M.D., CFO & Head of Corp. Devel. (Age 44)
  • Mr. John J. Keilty, Chief Data Sciences Officer
  • Mr. Joe Burns Ph.D., Head of Biology & VP

When did Decibel Therapeutics IPO?

(DBTX) raised $100 million in an initial public offering on Friday, February 12th 2021. The company issued 5,900,000 shares at $16.00-$18.00 per share. Citigroup, BMO Capital Markets, SVB Leerink and Barclays acted as the underwriters for the IPO.

What is Decibel Therapeutics' stock symbol?

Decibel Therapeutics trades on the NASDAQ under the ticker symbol "DBTX."

Who are Decibel Therapeutics' major shareholders?

Decibel Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Marquette Asset Management LLC (0.07%). Company insiders that own Decibel Therapeutics stock include Anna Trask, Casdin Partners Master Fund, L, Laurence Reid and Plc Glaxosmithkline.
View institutional ownership trends for Decibel Therapeutics
.

Which institutional investors are buying Decibel Therapeutics stock?

DBTX stock was bought by a variety of institutional investors in the last quarter, including Marquette Asset Management LLC. Company insiders that have bought Decibel Therapeutics stock in the last two years include Casdin Partners Master Fund, L, Laurence Reid, and Plc Glaxosmithkline.
View insider buying and selling activity for Decibel Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Decibel Therapeutics?

Shares of DBTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Decibel Therapeutics' stock price today?

One share of DBTX stock can currently be purchased for approximately $4.32.

How much money does Decibel Therapeutics make?

Decibel Therapeutics has a market capitalization of $107.67 million.

How many employees does Decibel Therapeutics have?

Decibel Therapeutics employs 40 workers across the globe.

What is Decibel Therapeutics' official website?

The official website for Decibel Therapeutics is decibeltx.com.

Where are Decibel Therapeutics' headquarters?

Decibel Therapeutics is headquartered at 1325 Boylston Street Suite 500, Boston MA, 02215.

How can I contact Decibel Therapeutics?

Decibel Therapeutics' mailing address is 1325 Boylston Street Suite 500, Boston MA, 02215. The company can be reached via email at [email protected].


This page was last updated on 1/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.